On August 13, UNISOUND rose 5.46% in regular trading, trading at HK$77.3/share, with turnover of approximately HK$54.49 million.

On the news front, the company officially released its self-developed medical imaging multimodal large model U2-RadiMed on the same day. The launch marks UNISOUND's extension of its large model capabilities into the medical imaging domain, completing its layered product architecture spanning from the general-purpose foundation model U2, to the specialized U2-Med healthcare model, and now to the medical imaging multimodal model, further consolidating the company's technology positioning in the medical AI space.

The announcement follows a series of recent positive developments. In late July, UNISOUND released its U2-Med model covering clinical, medical insurance, and pharmaceutical applications, ranking first in both the full-modality large model and AI agent categories in the MedBench benchmark. The company also signed AI deployment projects with multiple top-tier hospitals. Separately, UNISOUND guided first-half revenue of RMB 5.3-5.8 billion, representing 31%-43% year-over-year growth, with large model intelligent agent business surging over 200% year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)